Targeting RNA to treat neuromuscular disease.

Targeting RNA to treat neuromuscular disease.

The development of effective therapies for neuromuscular disorders such as Duchenne muscular dystrophy (DMD) is hampered by considerable challenges: skeletal muscle is the most abundant tissue in the body, and many neuromuscular disorders are multisystemic conditions. However, despite these barriers...

Descripció completa

Dades bibliogràfiques
Autors principals:	Muntoni, F, Wood, M
Format:	Journal article
Idioma:	English
Publicat:	2011

Ítems similars

RNA-targeted splice-correction therapy for neuromuscular disease.
per: Wood, M, et al.
Publicat: (2010)

Syncoilin upregulation in muscle of patients with neuromuscular disease.
per: Brown, S, et al.
Publicat: (2005)

Splicing therapy for neuromuscular disease.
per: Douglas, A, et al.
Publicat: (2013)

Syncoilin expression in neuromuscular disorders
per: Torelli, S, et al.
Publicat: (2001)

Syncoilin expression in neuromuscular disorders.
per: Howman, E, et al.
Publicat: (2001)

Establishment and application of clinical biobanks in treating neuromuscular diseases
per: Ya-wen ZHAO, et al.
Publicat: (2016-10-01)

Emerging oligonucleotide therapeutics for rare neuromuscular diseases
per: Aoki, Y, et al.
Publicat: (2021)

Editorial: Genome and transcriptome editing to understand and treat neuromuscular diseases
per: Rika Maruyama, et al.
Publicat: (2023-03-01)

RNA interference: from model organisms towards therapy for neural and neuromuscular disorders.
per: Buckingham, S, et al.
Publicat: (2004)

Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases
per: Anja Holm, et al.
Publicat: (2022-12-01)

Systemic delivery of MicroRNA using recombinant adeno-associated virus serotype 9 to treat neuromuscular diseases in rodents
per: Pourshafie, N, et al.
Publicat: (2018)

Emergency neuromuscular admissions are avoidable: a regional audit of unplanned hospital admissions of neuromuscular patients 2009-2011: final results and recommendations.
per: Jaffer, F, et al.
Publicat: (2013)

RNA Targeting in Inherited Neuromuscular Disorders: Novel Therapeutic Strategies to Counteract Mis-Splicing
per: Veronica Verdile, et al.
Publicat: (2021-10-01)

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders
per: Min-Suk Yoon, et al.
Publicat: (2015-07-01)

Multiple roles of integrin-α3 at the neuromuscular junction.
per: Ross, J, et al.
Publicat: (2017)

Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications
per: Yu-Fu Wu, et al.
Publicat: (2025-02-01)

Abdominal compartment syndrome successfully treated with neuromuscular blockade
per: Kris T Chiles, et al.
Publicat: (2011-01-01)

Diseases of the neuromuscular junction.
per: McConville, J, et al.
Publicat: (2002)

Diagnosing Neuromuscular Diseases
per: Alberto L. Dubrovsky
Publicat: (2018-08-01)

Neuromuscular Diseases and Bone
per: Giovanni Iolascon, et al.
Publicat: (2019-11-01)

Neuromuscular diseases and anesthesia
per: Antonijević Vesna, et al.
Publicat: (2018-01-01)

Role of RNA Binding Proteins with prion-like domains in muscle and neuromuscular diseases
per: Gina Picchiarelli, et al.
Publicat: (2020-03-01)

Protein defects in neuromuscular diseases
per: Vainzof M., et al.
Publicat: (2003-01-01)

Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
per: Mariot, V, et al.
Publicat: (2017)

Neuromuscular Blockade for Cardiac Arrest Patients Treated With Targeted Temperature Management: A Systematic Review and Meta-Analysis
per: Tong Lin, et al.
Publicat: (2022-05-01)

Critical Illness Neuromuscular Disease
per: J Gordon Millichap
Publicat: (1995-02-01)

Neuromuscular disease: 2023 update
per: Marta Margeta
Publicat: (2023-02-01)

Modeling neuromuscular diseases in zebrafish
per: Jaskaran Singh, et al.
Publicat: (2022-12-01)

Neuromuscular diseases: revisiting the "overtraining"
per: Marco Orsini, et al.
Publicat: (2014-04-01)

Editorial: Imaging of Neuromuscular Diseases
per: Jordi Diaz-Manera, et al.
Publicat: (2021-12-01)

Management of patients with neuromuscular disease /
per: Bach, John R., 1950-
Publicat: (c200)

Development of a high-throughput tailored imaging method in zebrafish to understand and treat neuromuscular diseases
per: Léa Lescouzères, et al.
Publicat: (2022-09-01)

Doenças neuromusculares Neuromuscular disorders
per: Umbertina C. Reed
Publicat: (2002-08-01)

The Impact of Mitochondrial Deficiencies in Neuromuscular Diseases
per: Judith Cantó-Santos, et al.
Publicat: (2020-10-01)

Predictors of overload in parents of children with neuromuscular diseases
per: A. A. Rodríguez, et al.
Publicat: (2024-02-01)

Molecular targets for autoimmune and genetic disorders of neuromuscular transmission.
per: Vincent, A, et al.
Publicat: (2000)

Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction.
per: Arimura, S, et al.
Publicat: (2014)

RNA and glia at the Drosophila neuromuscular junction: importance for synaptic plasticity
per: Gala, DS
Publicat: (2023)

Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies.
per: Robb, SA, et al.
Publicat: (2011)

Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
per: Virginie Mariot, et al.
Publicat: (2017-11-01)